Level Biotechnology

Level Biotechnology Current Ratio

The Current Ratio of Level Biotechnology (3118.TWO) as of Oct 23, 2026 is 1.69. In the previous year, Current Ratio was 3.70 — a change of -54.22% (lower).

Current Ratio

1.69

YoY

-54.22%

Last updated:

Current Ratio of Level Biotechnology is 2025 1.69 . Current Ratio of Level Biotechnology was 2024 3.70 . It decreases by -54.22% lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Level Biotechnology Stock analysis

What does Level Biotechnology do? Level Biotechnology, Inc. generates revenue through the sale of biotechnological services and products. The company offers cell culture series, immune protein series, gene nucleic acid and molecular biology series, and instrument series to customers in the domestic market. Preclinical testing services, including genetic toxicity testing, general toxicology testing, reproductive toxicology testing, pharmacokinetic testing, and biocompatibility testing, are also provided as key revenue streams. Domestic market buyers primarily include research institutions and pharmaceutical companies seeking advanced biotech solutions. The firm's product portfolio targets the biotechnology and pharmaceutical sectors, with a focus on domestic customers. Cell culture series and molecular biology series are essential for laboratory research, while immune protein series supports immunological studies. Preclinical testing services cater to pharmaceutical firms requiring regulatory compliance for drug development. All products and services are distributed exclusively within the domestic market, ensuring focused market penetration and customer relationships. Level Biotechnology's revenue model relies on consistent demand for biotech products and testing services from domestic clients. The company's domestic market distribution strategy allows for tailored service delivery and strong client retention. By specializing in cell culture, molecular biology, and preclinical testing, Level Biotechnology maintains a competitive edge in the local biotech industry. Level Biotechnology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Level Biotechnology stock

Current Ratio of Level Biotechnology is 1.69 in 2025.

Current Ratio of Level Biotechnology changed from 3.70 to 1.69, representing a -54.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Ratio Level Biotechnology since 2006 – with annual values, charts, and detailed analysis.

The Current Ratio measures a company's ability to pay short-term obligations. A ratio above 1 indicates that current assets exceed current liabilities.

Current Ratio = Current Assets / Current Liabilities

A 'good' varies by industry and company stage. On Eulerpool, you can compare Current Ratio's Level Biotechnology with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Level Biotechnology

All Key Metrics — Level Biotechnology